Opinion|Videos|December 10, 2024
Key Data Supporting the Use of Rebyota in Patients With Recurrent C Difficile Infections
Author(s)Paul Feuerstadt, MD, FACG, AGAF
Key Takeaways
- Rebyota's FDA approval was based on clinical trial data showing significant reduction in CDI recurrence rates compared to placebo.
- The pivotal trial was a randomized, double-blind, placebo-controlled study demonstrating Rebyota's efficacy in recurrent CDI.
The panelist discusses Rebyota, a treatment approved by the FDA for preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment for recurrent C difficile infections.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the key data that led to the FDA approval of Rebyota for recurrent C difficile infection?
- Who are the target patient populations for Rebyota?
Advertisement
Related to this article
A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.
Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.
SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.
Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Health Equity & Access Weekly Roundup: November 6, 2026
3
Medicaid Cuts and Caregiving in Congress: Andy Kim
4
COPD’s Old Narrative Is Outdated, GOLD Leaders Say in 2027 Update
5